HEP-1 (Gepon) vs Thymosin Alpha-1

HEP-1 (Gepon): Russian-approved 14-amino-acid immunomodulator derived from the ezrin protein. Typical dose 1,000-10,000 mcg. Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. Both fall under the Immune category.

Stacking HEP-1 (Gepon) with Thymosin Alpha-1 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

HEP-1 (Gepon) is typically dosed: Once daily, oral or rectal for HIV/AIDS adjunct (Russian clinical); Topical 3-4 times daily for Recurrent herpes (Russian clinical); Intranasal or oral for Mucosal immunity research. Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support.

HEP-1 (Gepon): Not FDA approved. Approved in Russia as Gepon. Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted.